STEP – The lived experience of Parkinson’s disease
sponsored by UCB
Author: UCBPublished: 31 January 2018
Prep: Cook: Serves:
An innovative market research (“research”) programme, STEP™, aims to move beyond the focus on Parkinson’s symptoms to examine the real lived experience of Parkinson’s. We look at how the STEP™ programme sheds light on the impact of the condition on a person’s life, relationships and identity – and how it can help address the multiple dimensions of the condition
When people think of Parkinson’s, they are likely to think of the most widely recognised symptoms such as tremor and movement difficulties. But, as people living with the condition will emphasise, its impact goes much wider, affecting a person’s relationships and their sense of self.
A recent piece of research aimed to gain a fuller understanding of this impact. STEP™ was an innovative, ethnographic and context lab research programme undertaken in the UK, US and Canada. The programme included 63 people with Parkinson’s, between the ages of 40 and 76, who had lived with Parkinson’s for between six months and 21 years and had varied experiences of treatment. A total of 19 partners and those providing care, 18 healthcare professionals and other Parkinson’s experts also took part.
Researchers visited participants at home to glean first-hand experiences about living with the condition. People living with Parkinson’s and their loved ones were asked to speak freely about their experiences, and some also took part in group discussions where they shared the aspects that mattered most to them.
“People with Parkinson’s spoke freely about living with the condition”
The academics – who were anthropologists and strategists – also held in-depth one-to-one interviews with healthcare professionals and other experts who have frequent contact with people living with the condition, and visited the places where they interact.
The findings may not be that surprising to those familiar with Parkinson’s (see key insights from STEP™ research below), but researchers hope that this evidence-based research will help those who look after people with Parkinson’s to develop more appropriate and holistic approaches, with the confidence that they are addressing real needs. By giving a voice to people with Parkinson’s, STEP™ may well lead to solutions that improve how an individual views their experience of the condition.
Key insights from STEP™ research
In addition to key research insights, the findings suggest that people with Parkinson’s first experience the condition as a lifestyle disorder, then as intermittent periods of capability and loss, and finally as a loss of independence. Often forgotten in this are their loved ones who also experience a transition, with partners, friends and family members often becoming full-time caregivers as the condition progresses.
“By giving a voice to people with Parkinson’s, STEP™ may lead to better solutions”
Based on these insights, the following phases have been identified throughout the patient and loved-one or caregiver journey as Parkinson’s unfolds:
Pre-diagnosis – a person notices a ‘first sign’ such as a finger twitch. At first, these early symptoms are often rationalised as part of the natural ageing process.
Diagnosis – a moment of transition that alters a person’s understanding of their own physical health.
Lifestyle – a period of adjustment to a new way of life marked by mild to moderate limitations: Parkinson’s feels like a bother, not a disease.
Straddle – moving back and forth between pre-Parkinson’s life in “on” (medication is working and symptoms reduced) and glimpses of the disease in “off” moments (medication effect has worn off and symptoms become more severe).
Disease – after years of navigating “on” and “off” periods, the experience of Parkinson’s transforms into a ‘disease’ in the medical sense of the word. Unmanageable fluctuations, loss of independence, development of other conditions and medication side-effects begin to affect the patient’s entire personhood as they know it.
While every individual’s journey will be unique and complex, these common attributes allow those providing support to think about more than managing the physical symptoms. Incorporating the social, emotional and relationship aspects of living with Parkinson’s – and offering solutions as appropriate – can help both the person with Parkinson’s and their loved ones or caregivers to maximise positive outcomes along their journey. Ref: HQ/1217/NU/00088
UCB is a global biopharmaceutical company with a focus on neurology.
UCB is committed to identifying and addressing the unmet needs of people living with Parkinson’s disease to enable them to have a more engaged life every day.
This research was conducted by Idea Couture, now part of Cognizant Digital Works on behalf of UCB.
The authors thank the people living with Parkinson’s, and all other participants in addition to the researchers and their teams who contributed to this research.
STEP™ is a trademark of UCB Biopharma SPRL.
To access to the full report, please visit ucb.com.
This article is sponsored by UCB. The information in this article is given for information purposes only and does not represent an endorsement by the EPDA of any particular treatments, products or companies. This article is not a substitute for advice from your doctor, pharmacist or other healthcare professional. Parkinson’s Life makes no representations or warranties of any kind, express or implied, about the completeness or accuracy of information provided.
Parkinson’s AI trial launched by Chinese tech giant
The study will take place in London
2 days ago
Wearable device for Parkinson’s disease raises $10m in funding
UK-based tech company Charco Neurotech has secured $10 million in seed investment funding to support the launch of a non-invasive wearable device designed for people with Parkinson’s disease. CUE1 is a circular device worn on the sternum, which is designed to help alleviate Parkinson’s symptoms through specialised vibrations that are personalised for each patient. The investment round, which was co-led by venture capital company Amadeus Capital Partners and growth fund managers Parkwalk Advisors, is the largest European seed financing in 2021 for a heath technology device – and the sixth largest globally. Lucy Jung, co-founder and CEO of Charco Neurotech, said: “This funding will enable us to proceed with our first, limited launch, while we work to ensure our manufacturing line is robust and produces consistent high quality devices.” Charco also recently announced a new partnership with the European Parkinson’s Disease Association (EPDA), to help increase the availability of Charco’s…
An international team led by the University of Ottawa in Canada will study whether the scent-processing nerves inside the nose may play a part in the development of Parkinson’s disease. The researchers will explore potential connections between inflammation, environmental exposures in the nasal cavity, odour processing centres in the brain and Parkinson’s-related genes. The scientists hope that if the study indicates that Parkinson’s starts in the nose, early signs of the condition could potentially be detected sooner. This research, which will use human and animal models, has been made possible by a US $9m grant from the Aligning Science Across Parkinson’s (ASAP) initiative, which aims to improve understanding of the causes of the condition. “This grant will allow us to explore an understudied but important aspect of Parkinson’s, which could lead to new approaches for early treatment and prevention,” said Professor Michael Schlossmacher, team leader of the study.
Study finds gene therapy may restore effects of Parkinson’s drug
Levodopa is a drug commonly used to treat Parkinson’s as it helps to increase dopamine levels in the brain and improve problems with movement. In later stages of the condition, however, this treatment can become less effective. Now, findings from a US preclinical study have suggested that a new gene therapy may help to restore the effects of levodopa in people with the condition. The researchers used mice models of Parkinson’s to test the effects of the gene therapy, targeting a small region in the brain where dopamine-releasing neurons are present. They found that the therapy increased the neurons’ ability to convert levodopa to dopamine – and discovered that damage to the mitochondria in dopamine-releasing neurons may be enough to trigger Parkinson’s onset. The scientists hope their findings will encourage the development of therapies to preserve the function of these neurons, and support patients in the later stages of Parkinson’s.